IBDEI0HP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8257,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,8258,0)
 ;;=201.90^^35^482^83
 ;;^UTILITY(U,$J,358.3,8258,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8258,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,8258,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,8258,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,8259,0)
 ;;=785.6^^35^482^89
 ;;^UTILITY(U,$J,358.3,8259,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8259,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,8259,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,8259,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,8260,0)
 ;;=200.20^^35^482^90
 ;;^UTILITY(U,$J,358.3,8260,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8260,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,8260,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,8260,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,8261,0)
 ;;=202.00^^35^482^92
 ;;^UTILITY(U,$J,358.3,8261,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8261,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,8261,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,8261,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,8262,0)
 ;;=200.10^^35^482^91
 ;;^UTILITY(U,$J,358.3,8262,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8262,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,8262,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,8262,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,8263,0)
 ;;=273.3^^35^482^93
 ;;^UTILITY(U,$J,358.3,8263,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8263,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,8263,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,8263,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,8264,0)
 ;;=203.00^^35^482^103
 ;;^UTILITY(U,$J,358.3,8264,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8264,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,8264,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,8264,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,8265,0)
 ;;=203.01^^35^482^105
 ;;^UTILITY(U,$J,358.3,8265,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8265,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,8265,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,8265,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,8266,0)
 ;;=238.6^^35^482^108
 ;;^UTILITY(U,$J,358.3,8266,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8266,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,8266,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,8266,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,8267,0)
 ;;=205.00^^35^482^4
 ;;^UTILITY(U,$J,358.3,8267,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8267,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,8267,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,8267,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,8268,0)
 ;;=205.01^^35^482^6
 ;;^UTILITY(U,$J,358.3,8268,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8268,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,8268,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,8268,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,8269,0)
 ;;=205.10^^35^482^19
 ;;^UTILITY(U,$J,358.3,8269,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8269,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,8269,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,8269,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,8270,0)
 ;;=205.11^^35^482^21
 ;;^UTILITY(U,$J,358.3,8270,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8270,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,8270,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,8270,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,8271,0)
 ;;=289.0^^35^482^55
 ;;^UTILITY(U,$J,358.3,8271,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8271,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,8271,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;
 ;;$END ROU IBDEI0HP
